Fig. 2.
A comparison of the sympathoexcitatory response elicited by bolus versus intermittent orexin-A at both (A) suprathreshold and (B) subthreshold doses. Single administration of orexin-A (100 pmol; n = 4) and orexin-A (100 pmol) + Almorexant (AXT) at 75 mg⋅kg−1 (n = 5) did not elevate sympathetic activity. (C) No significant changes were observed compared with PBS control (n = 5) when sSNA is measured as % range. Grouped data for the % range from every treatment group are compared. AXT at 75 mg⋅kg−1 (n = 4) produced no effect on baseline sympathetic activity. (D) AXT at 30 mg⋅kg−1 (n = 5) and 75 mg⋅kg−1 (n = 5) attenuated the effect of intermittent orexin-A (10 pmol × 10; n = 5) on sSNA. Statistical significance was determined using one-way analysis of variance followed by Holm-Sidak correction to compare the effects with the control. Data are expressed as mean ± S.E.M. ****P < 0.0001; ***P < 0.001; *P < 0.05. #P < 0.05 compared with intermittent orexin-A (10 pmol × 10).